Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome

Prota Therapeutics' long-term peanut allergy study published in Allergy confirms clinical remission as the optimal treatment outcome, with high-dose oral immunotherapies PRT120 and PRT100 showing lasting benefits, including improved quality of life and reduced allergic reactions.